Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Industrias
Biotecnología
Sector
Sanidad
Identificador
Número de Identificación Internacional de Valores (ISIN)
AU000000IMM6
Teletipo de bolsa (ticker) principal
IMM
Knockouts
<contenedor>Datos LSX</contenedor> · Datos financieros de FactSet
